NCT05001412 2021-08-12
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 1 Unknown
Clinical Trials
10 trialsNCT04665362 2021-01-22
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 1 Unknown
NCT04390984 2021-01-11
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT03645200 2019-04-25
Treatment of Carrying TP53 Harmful Mutations
Tianjin Medical University Second Hospital
Phase 1 Unknown
NCT03243643 2017-09-08
HS:Hansoh;
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT03276156 2017-09-08
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
Zhejiang Cancer Hospital
Phase 1 Unknown
NCT03026881 2017-03-07
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT03050411 2017-02-10
Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Peking University Third Hospital
Phase 1 Unknown
NCT02691871 2016-02-25
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Unknown
NCT00633490 2008-07-22
Study of Apatinib as an Inhibitor of Tumor Angiogenesis
Fudan University
Phase 1 Unknown